

NOTE: PLEASE REFER TO THE BACK OF THIS REQUISITION FOR SPECIMEN HANDLING INSTRUCTIONS
MICHIGAN MEDICINE

DEPARTMENT OF PATHOLOGY

Testing / Diagnostic / Screening Requisition -
Molecular Diagnostics Laboratory Requisition

RESULTS
REPORTING
LOCATION
CODE:

MRN

BIRTHDATE

NAME

CSN

Routine
 STAT

ORDER DATE: ____ / ____ / ____
(mm/dd/yyyy)

ICD-10 Code/Diagnosis:		Ordering Clinician to receive report: <input type="checkbox"/> See label above	
Collected by:		UMHS Dr. #:	
Collected Date: ____ / ____ / ____	Collection Time: ____ : ____ am/pm	Attending Physician: (if different from above)	UMHS Dr. #:

MOLECULAR DIAGNOSTIC LABORATORY

This request to order tests from the Molecular Diagnostics Laboratory certifies to the laboratory that (1) the ordering physician has obtained informed consent from the patient as required by applicable state or federal laws for each test ordered and (2) the ordering physician has authorization from the patient permitting the Molecular Diagnostics Laboratory to report results for each test ordered to the ordering physician.

For general information, call the Laboratory at 936-0565, M - F 8:00 - 4:30

TESTING WILL BE DELAYED OR NOT PERFORMED IF REQUISITION IS NOT COMPLETE!

SPECIMEN TYPE

BLOOD BONE MARROW PARAFFIN BLOCK
(SOURCE) TISSUE
(SEND FROZEN) SOURCE OTHER
SOURCE

SURG PATH ID#

PATIENT HISTORY/DIAGNOSIS:

HEMATOLOGY/ONCOLOGY

ACUTE MYELOID LEUKEMIA

- Myeloid NGS Panel
- TP53 Mutation in Malignancy
- NPM1 Mutation
- FLT3 Mutation
- CEPBA Mutation
- IDH1 and IDH2 Mutations
- KIT D816V Mutation
- KIT Mutation for AML - Exons 8, 17
- PML/RARA t(15;17) Translocation, Quantitative

MYELOID NEOPLASMS

- Myeloid NGS Panel
- TP53 Mutation in Malignancy
- JAK2 V617F Mutation
- JAK2 Exon 12 Mutation
- CALR Mutation
- MPL Mutation
- KIT D816V Mutation
- BCR/ABL1 Analysis, Quantitative
- BCR/ABL1 Kinase Domain Mutation

LYMPHOMA

- B Cell Clonality (IGH Gene Rearrangement)
- B Cell Clonality (IGK Gene Rearrangement)
- T Cell Clonality (TRG Gene Rearrangement)
- T Cell Clonality (TRB Gene Rearrangement)
- TP53 Mutation in Malignancy
- IGH/BCL2 t(14;18) Translocation (PCR)
- IGH/BCL2 t(14;18) Translocation (FISH)
- BCL6 (3q27) Rearrangement (FISH)
- MYC (8q24) Rearrangement (FISH)
If MYC is positive, perform: IGH/BCL2 (FISH) BCL6 (FISH)
- MALT1 (18q21) Rearrangement (FISH)
- MYD88 (L265P) Mutation
- BRAF V600E/V600K Mutations

GASTROINTESTINAL AND HEPATOIBILIARY

- T, L Colorectal Cancer NGS Panel
- T, L KRAS Mutation
- T, L NRAS Mutation
- T, L BRAF V600E/V600K Mutation
- L Microsatellite Instability Analysis
- L If MSI-H, perform BRAF V600E MLH1 Promoter Methylation
- T, L MLH1 Promoter Methylation
- T, L Germline MLH1 Promoter Methylation
- T, L UGT1A1 Promoter Genotype
- T, L HER2 (FISH)
- L FGFR2 (10q26) Rearrangement by FISH
- L Biliary Tract Malignancy (FISH)
- L KIT Mutation - Exons 9,11,13,17
- T, L If KIT is negative, perform: PDGFRα BRAF V600E
- T, L PDGFRα Mutation for GIST

CENTRAL NERVOUS SYSTEM TUMORS

- L Cancer Cytogenomic Array-FFPE Tissue
- L Solid Tumor NGS Panel
- L IDH1 and IDH2 Mutations for Glioma
- L 1p/19q Deletion (FISH)
- T, L BRAF (7q34) Rearrangement (FISH)
- L BRAF V600E/V600K Mutations
- L MGMT Promoter Methylation
- L TERT Promoter Mutation

LUNG CANCER

- T, L Lung Cancer NGS Panel
- T, L EGFR Mutation
- T, L BRAF V600E/V600K Mutations
- T, L KRAS Mutation
- T, L ALK Rearrangement for NSCLC (FISH)
- T, L ROS1 (6q22) Rearrangement (FISH)
- T, L RET (10q11) Rearrangement (FISH)
- T, L MET Amplification by FISH
- S, T Mesothelioma FISH

MELANOMA

- S, T Cancer Cytogenomic Array-FFPE Tissue
- S, T Melanoma NGS Panel
- S, T BRAF V600E/V600K Mutations
- S, T KIT Mutation for Melanoma - Exons 11,13,17
- S, T NRAS Mutation
- S, T BRAF (7q34) Rearrangement (FISH)
- S, T TERT Promoter Mutation

THYROID CANCER

- S, T Solid Tumor NGS Panel
- S, T BRAF V600E/V600K Mutation
- S, T BRAF (7q34) Rearrangement FISH
- S, T TERT Promoter Mutation
- S, T RET Mutation

SARCOMA

- S, T SYT/SSX Translocation (PCR)
- L PAX/FOXO1 Translocation (PCR)
- L EWSR1/WT1 Translocation (PCR)
- S, T EWSR1/ATF1 Translocation (PCR)
- S, T EWSR1/FLI1 & EWSR1/ERG Translocation (PCR)
- B EWSR1 (22q12) Rearrangement (FISH)
- S, T MDM2 Amplification (FISH)
- S, T CIC (19q13) Rearrangement (FISH)
- S, T PDGFB (22q13) Rearrangement (FISH)
- S, T NR4A3 (9q22-9q31) Rearrangement by (FISH)
- S, T DDIT3 (12q13) Rearrangement (FISH)

BREAST CANCER

- S, T Solid Tumor NGS Panel
- S, T HER2 (FISH)
- S, T PIK3CA Mutation

GENITOUREINARY CANCER

- S, T i(12p) assessment by Cancer Cytogenomic Array-FFPE Tissue
- S, T TFE3-FISH (Cytogenetics)

- S, T TFEB-FISH (Cytogenetics)
- S, T ERG-FISH (Cytogenetics)
- S, T Solid Tumor NGS Panel
- S, T FGFR Translocation/Mutation
- S, T TERT Promoter Mutation

MISCELLANEOUS

- S, T Cancer Cytogenomic Array-FFPE Tissue
- S, T Solid Tumor NGS Panel
- S, T HER2 (FISH)
- S, T Mesothelioma FISH
- S, T Microsatellite Instability
- S, T If MSI-H perform MLH1 Promoter Methylation
- S, T Germline MLH1 Promoter Methylation
- S, T Specimen Identity (discuss with Taulbee/Kunju/ Pantanowitz)

ENDOMETRIAL CANCER

BONE MARROW TRANSPLANT ENGRAFTMENT ASSESSMENT

- S, T POLE Mutation
- S, T Microsatellite Instability
- S, T If MSI-H perform MLH1 Promoter Methylation
- S, T MLH1 Promoter Methylation
- S, T Pre-BMT RECIPIENT, Engraftment Analysis
- S, T Pre-BMT DONOR, Engraftment Analysis
- S, T DONOR FOR: _____ MRN: _____
- S, T Post-BMT Engraftment Analysis (Pre-BMT MUST have been previously performed)
- S, T Non-myeloablative transplant? Yes No
- S, T Fractionation? Yes No
- S, T Days post-transplant _____